vs
ANI PHARMACEUTICALS INC（ANIP）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是Ribbon Communications Inc.的1.5倍（$247.1M vs $162.6M），Ribbon Communications Inc.净利率更高（54.8% vs 11.1%，领先43.6%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs -10.3%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs -8.1%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
ANIP vs RBBN — 直观对比
营收规模更大
ANIP
是对方的1.5倍
$162.6M
营收增速更快
ANIP
高出39.9%
-10.3%
净利率更高
RBBN
高出43.6%
11.1%
两年增速更快
ANIP
近两年复合增速
-8.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $162.6M |
| 净利润 | $27.5M | $89.1M |
| 毛利率 | — | 42.9% |
| 营业利润率 | 14.1% | 37.6% |
| 净利率 | 11.1% | 54.8% |
| 营收同比 | 29.6% | -10.3% |
| 净利润同比 | 367.5% | — |
| 每股收益（稀释后） | $1.14 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPRBBN
| Q1 26 | — | $162.6M | ||
| Q4 25 | $247.1M | $227.3M | ||
| Q3 25 | $227.8M | $215.4M | ||
| Q2 25 | $211.4M | $220.6M | ||
| Q1 25 | $197.1M | $181.3M | ||
| Q4 24 | $190.6M | $251.4M | ||
| Q3 24 | $148.3M | $210.2M | ||
| Q2 24 | $138.0M | $192.6M |
净利润ANIPRBBN
| Q1 26 | — | $89.1M | ||
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-12.1M | ||
| Q2 25 | $8.5M | $-11.1M | ||
| Q1 25 | $15.7M | $-26.2M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $-13.4M | ||
| Q2 24 | $-2.3M | $-16.8M |
毛利率ANIPRBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | — | 53.3% | ||
| Q3 25 | — | 50.1% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 45.4% | ||
| Q4 24 | — | 55.7% | ||
| Q3 24 | — | 52.1% | ||
| Q2 24 | — | 50.8% |
营业利润率ANIPRBBN
| Q1 26 | — | 37.6% | ||
| Q4 25 | 14.1% | 4.1% | ||
| Q3 25 | 15.9% | 1.3% | ||
| Q2 25 | 6.6% | 1.9% | ||
| Q1 25 | 13.3% | -10.8% | ||
| Q4 24 | -2.3% | 13.2% | ||
| Q3 24 | -13.8% | -0.4% | ||
| Q2 24 | 3.7% | -1.0% |
净利率ANIPRBBN
| Q1 26 | — | 54.8% | ||
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -5.6% | ||
| Q2 25 | 4.0% | -5.0% | ||
| Q1 25 | 8.0% | -14.5% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | -6.4% | ||
| Q2 24 | -1.7% | -8.7% |
每股收益（稀释后）ANIPRBBN
| Q1 26 | — | $0.50 | ||
| Q4 25 | $1.14 | $0.50 | ||
| Q3 25 | $1.13 | $-0.07 | ||
| Q2 25 | $0.36 | $-0.06 | ||
| Q1 25 | $0.69 | $-0.15 | ||
| Q4 24 | $-0.45 | $0.05 | ||
| Q3 24 | $-1.27 | $-0.08 | ||
| Q2 24 | $-0.14 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $67.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $419.1M |
| 总资产 | $1.4B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPRBBN
| Q1 26 | — | $67.6M | ||
| Q4 25 | $285.6M | $96.4M | ||
| Q3 25 | $262.6M | $74.8M | ||
| Q2 25 | $217.8M | $60.5M | ||
| Q1 25 | $149.8M | $71.2M | ||
| Q4 24 | $144.9M | $87.8M | ||
| Q3 24 | $145.0M | $37.2M | ||
| Q2 24 | $240.1M | $64.6M |
总债务ANIPRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | $342.1M | ||
| Q3 25 | — | $344.3M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | — | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
股东权益ANIPRBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $540.7M | $449.0M | ||
| Q3 25 | $505.8M | $360.1M | ||
| Q2 25 | $436.8M | $370.4M | ||
| Q1 25 | $418.6M | $381.8M | ||
| Q4 24 | $403.7M | $404.6M | ||
| Q3 24 | $405.9M | $395.5M | ||
| Q2 24 | $455.8M | $405.0M |
总资产ANIPRBBN
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.1B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B |
负债/权益比ANIPRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPRBBN
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $29.2M | ||
| Q3 25 | $44.1M | $26.5M | ||
| Q2 25 | $75.8M | $-795.0K | ||
| Q1 25 | $35.0M | $-3.5M | ||
| Q4 24 | $15.9M | $61.8M | ||
| Q3 24 | $12.5M | $-14.8M | ||
| Q2 24 | $17.4M | $-9.8M |
自由现金流ANIPRBBN
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $27.3M | ||
| Q3 25 | $38.0M | $21.0M | ||
| Q2 25 | $71.8M | $-6.5M | ||
| Q1 25 | $32.5M | $-15.7M | ||
| Q4 24 | $13.5M | $53.8M | ||
| Q3 24 | $7.7M | $-23.7M | ||
| Q2 24 | $13.0M | $-12.9M |
自由现金流率ANIPRBBN
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 12.0% | ||
| Q3 25 | 16.7% | 9.7% | ||
| Q2 25 | 34.0% | -2.9% | ||
| Q1 25 | 16.5% | -8.7% | ||
| Q4 24 | 7.1% | 21.4% | ||
| Q3 24 | 5.2% | -11.3% | ||
| Q2 24 | 9.4% | -6.7% |
资本支出强度ANIPRBBN
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 0.9% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 1.3% | 6.7% | ||
| Q4 24 | 1.3% | 3.2% | ||
| Q3 24 | 3.2% | 4.2% | ||
| Q2 24 | 3.2% | 1.6% |
现金转化率ANIPRBBN
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
